FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
March 15, 2024

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Joyce Frimpong, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ranjana H. Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Division of Oncology
Stanford University School of Medicine
Stanford, California

William J. Gradishar, MD
Professor of Medicine/Betsy Bramsen Professor of Breast Oncology
Chief, Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine at Northwestern University
Chicago, Illinois

Christopher H. Lieu, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology Program
University of Colorado
Aurora, Colorado

Ravi A. Madan, MD
(*Chairperson*)
Senior Clinician
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health (NIH)
Bethesda, Maryland

Jorge J. Nieva, MD
Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC)
Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Daniel Spratt, MD
Vincent K Smith Chair, Department of Radiation Oncology
Professor of Radiation Oncology and Urology
University Hospitals Seidman Cancer Center
Case Western Reserve University
Cleveland, Ohio

Neil Vasan, MD, PhD
Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Tara Frenkl, MD, MPH
Senior Vice President, Head of Oncology Development
Bayer Pharmaceuticals
Whippany, New Jersey

TEMPORARY MEMBERS (Voting)

John Deflice, MD
(Patient Representative)
Albuquerque, New Mexico

Sally Hunsberger, PhD
Mathematical Statistician
Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases
NIH
Bethesda, Maryland

Mary Kwok, MD
Clinical Associate Professor
Division of Hematology-Oncology
University of Washington
Seattle, Washington

Susan Lattimore, RN, GCPH
(Consumer Representative)
Assistant Professor, Pediatrics
Associate Director – The Hemostasis & Thrombosis Center
Oregon Health & Science University
Portland, Oregon

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD
(Afternoon session only)
Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc Theoret, MD
Deputy Center Director, OCE
Supervisory Assoicate Director (Acting)
OOD, OND, CDER, FDA

Nicole Verdun, MD
Super Office Director
Office of Therapeutic Products (OTP)
Center for Biologics Evaluation and Research (CBER)
FDA

Bindu Kanapuru, MD
Clinical Team Leader
Division of Hematologic Malignancies II (DHMII)
OOD, OND, CDER, FDA

Robert Sokolic, MD
Branch Chief
Malignant Hematology Branch (MHB)
Division of Clinical Evaluation Hematology (DCEH)
Office of Clinical Evaluation (OCE)
OTP, CBER, FDA

Helkha Peredo-Pinto, MD, MPH
(Morning session only)
Clinical Reviewer
MHB, DCEH, OCE, OTP, CBER, FDA

Cong Wang, PhD
(Morning session only)
Statistical Reviewer
Therapeutics Evaluation Branch 1 (TEB1)
Division of Biostatistics (DB)
Office of Biostatistics and Pharmacovigilance
(OBPV), CBER, FDA

Poornima Sharma, MD
(Afternoon session only)
Clinical Reviewer
MHB, DCEH, OCE, OTP, CBER, FDA

Xue (Mary) Lin, PhD
(Afternoon session only)
Statistical Reviewer
TEB1, DB, OBPV, CBER, FDA